Sanctuary Advisors LLC Takes $909,000 Position in Guardant Health, Inc. $GH

Sanctuary Advisors LLC purchased a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,062 shares of the company’s stock, valued at approximately $909,000.

Several other large investors have also recently added to or reduced their stakes in GH. Elyxium Wealth LLC acquired a new position in Guardant Health in the fourth quarter worth $35,000. Parallel Advisors LLC increased its stake in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after purchasing an additional 219 shares during the last quarter. Ascentis Independent Advisors acquired a new stake in shares of Guardant Health during the first quarter worth $38,000. Hollencrest Capital Management acquired a new stake in shares of Guardant Health during the first quarter worth $41,000. Finally, EFG International AG bought a new position in shares of Guardant Health in the 4th quarter worth about $41,000. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Trading Down 4.2%

Guardant Health stock opened at $161.50 on Friday. The stock has a market cap of $21.67 billion, a price-to-earnings ratio of -46.27 and a beta of 1.60. The company’s 50-day moving average price is $157.49 and its two-hundred day moving average price is $120.75. Guardant Health, Inc. has a 52 week low of $53.40 and a 52 week high of $176.58.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.34. The company had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. The company’s revenue was up 44.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.44) earnings per share. Research analysts expect that Guardant Health, Inc. will post -2.98 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. UBS Group set a $150.00 price target on shares of Guardant Health in a report on Wednesday, June 24th. Stephens increased their price objective on shares of Guardant Health from $170.00 to $195.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. BTIG Research raised their target price on shares of Guardant Health from $190.00 to $195.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Sanford C. Bernstein lifted their target price on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, July 2nd. Finally, Mizuho upped their target price on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $183.78.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, CEO Helmy Eltoukhy sold 100,000 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the completion of the transaction, the chief executive officer directly owned 2,012,919 shares of the company’s stock, valued at approximately $254,231,669.70. This trade represents a 4.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Amirali Talasaz sold 143,028 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $151.54, for a total value of $21,674,463.12. Following the transaction, the chief executive officer directly owned 1,881,336 shares of the company’s stock, valued at approximately $285,097,657.44. The trade was a 7.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 548,318 shares of company stock valued at $82,501,873. 5.60% of the stock is currently owned by company insiders.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.